Ridgeback Biotherapeutics LP, a closely held biotechnology company, and Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory ...
SARS-CoV-2 – the coronavirus that causes the disease COVID-19 – is completely new and attacks cells in a novel way. ...
As part of the government-wide effort to mitigate the spread of COVID-19 in U.S. communities, the U.S. Department of Health ...
A randomized, controlled clinical trial to evaluate the safety and efficacy of the investigational antiviral remdesivir in hospitalized adults diagnosed ...
Four research teams at Columbia University will share a $2.1 million grant to mount an aggressive effort to identify potential ...
Johnson & Johnson today announced that its Janssen Pharmaceutical Companies will expand its existing partnership with the Biomedical Advanced Research ...
The drug EIDD-1931 was effective against SARS and MERS viruses in the laboratory, and a modified version (EIDD-2801) could potentially ...
To support U.S. government medical countermeasure research and development in response to the COVID-19 outbreak, the Biomedical Advanced Research Development ...
Roche statement on 2019-nCoV (novel coronavirus) Basel, 31 January 2020 The World Health Organization (WHO) has declared a Public Health ...
Atriva Therapeutics GmbH has announced the successful conclusion and top-line results of its Phase I clinical trial for its lead ...
AbCellera Biologics Inc. this week announced that it was awarded a contract from the Defense Advanced Research Projects Agency (DARPA) to ...
Researchers at Texas Biomedical Research Institute in San Antonio have been awarded a $2 million dollar contract by the makers ...
The Defense Advanced Research Projects Agency (DARPA) launched the Pandemic Prevention Platform (P3) program in 2017, with the eventual goal of halting the spread ...
The etiological agent responsible for smallpox disease, Variola viridae (VARV) is responsible for the deaths of hundreds of millions of ...
The American Society for Microbiology’s ASM Biothreats 2018 meeting is taking place February 12-14, 2018 in Baltimore, Maryland. ASM Biothreats ...
The Biomedical Advanced Research and Development Authority (BARDA) is soliciting proposals for the advanced research and development of medical countermeasures ...
The development of anti-influenza drugs has been limited by the fact that animal models do not accurately reflect the infection ...
Emergent BioSolutions Inc. held a ribbon-cutting ceremony last week on May 10 to mark the formal opening of the company’s ...
The Biomedical Advanced Research and Development Authority (BARDA) has issued two pre-solicitation notices supporting mid- and late-phase development of medical countermeasures ...
A study led by scientists at the University of Texas Medical Branch Galveston National Laboratory and Mapp Biopharmaceutical has found ...
